The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
Open accessAbstract
Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between the in vitro activity and outcome from both in vivo and clinical studies. Using data generated by standardized broth microdilution and disk diffusion test methods, the Antifungal Susceptibility Subcommittee of the Clinical and Laboratory Standards Institute has now proposed interpretive breakpoints for voriconazole and Candida species. The MIC distribution for voriconazole was determined using a collection of 8,702 clinical isolates. The overall MIC 90 was 0.25 μg/ml and 99% of the isolates were inhibited at ≤1 μg/ml of voriconazole. Similar results were obtained for 1,681 Candida isolates (16 species) from the phase III clinical trials. Analysis of the available data for 249 patients from six phase III voriconazole clinical trials demonstrated a statistically significant correlation ( P = 0.021) between MIC and investigator end-of-treatment assessment of outcome. Consistent with parallel pharmacodynamic analyses, these data support the following MIC breakpoints for voriconazole and Candida species: susceptible (S), ≤1 μg/ml; susceptible dose dependent (SDD), 2 μg/ml; and resistant (R), ≥4 μg/ml. The corresponding disk test breakpoints are as follows: S, ≥17 mm; SDD, 14 to 16 mm; and R, ≤13 mm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Analysis of this dataset demonstrated a strong relationship between AUC/MIC and outcome.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [150]
In the citing paper
“Therapeutic success was observed in approximately 80% of patients with a 24-hour AUC/MIC greater than 25, whereas when the AUC/MIC was less than 25, clinical failure was noted in 45% of patients.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [150]
In the citing paper
“Indeed, scatterplots of anidulafungin MICs (Fig. 3a) and micafungin MICs (Fig. 3b) versus caspofungin MICs show high levels of correlation ( R = 0.83), with 92% (anidulafungin) to 97% (micafungin) of all MICs for the two comparisons within ± 2 log 2 dilutions of one another (230).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationWikler, M. A., & Clinical (2006) · Clinical and Laboratory Standards Institute eBooks · Cited by 2,842
Antibiotics in Laboratory Medicine.
Lorian, V. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,809
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Self-citationWalsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Self-citationRex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 705
Self-citationVoriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., Dupont, B., Torre‐Cisneros, J., Just‐Nübling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 676
Self-citation
Flagged first, then by citations
1 of the 43 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Florea, N. R., J. L. Kuti, and R. Quintiliani. 2002. Voriconazole: a novel azole antifungal. Formulary37:389-399.
Cited by
Sorted by citations
Items 201–258 of 258
Does One Voriconazole Breakpoint Suit All Candida Species?
Arendrup, M. C., & Denning, D. W. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00412-07 · Cited by 9
Gackowski, M., Froelich, A., Kordyl, O., Długaszewska, J., Kamińska, D., Schneider, R., & Osmałek, T. Z. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091218 · Cited by 8
Li, Y., Nguyen, M. H., Schmidt, S., Li, Z., Derendorf, H., & Clancy, C. J. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.02.006 · Cited by 8
Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.
Jones, R. N., Kirby, J. T., Messer, S. A., & Sheehan, D. J. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.01.018 · Cited by 8
Self-citationThe laboratory and clinical mycology
Pfaller, M. A., & McGinnis, M. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00004-9 · Cited by 8
Self-citationRementerı́a, A., Sánchez-Vargas, L. O., Villar, M., Casals, J. B., Carrillo‐Muñoz, A. J., Andrés, C. R., Eraso, E., & Quindós, G. (2007) · Journal of Chemotherapy · doi:10.1179/joc.2007.19.2.172 · Cited by 8
Susceptibility Test Methods: Yeasts and Filamentous Fungi
Johnson, E. M., Espinel-Ingroff, A. V., & Pfaller, M. A. (2011) · doi:10.1128/9781555816728.ch128 · Cited by 8
Self-citationÖz, Y., Dağ, İ., & Kiraz, N. (2011) · Mycopathologia · doi:10.1007/s11046-011-9459-x · Cited by 7
Salgado-Parreño, F. J., Alcoba-Flórez, J., Arias, Á., Moragues, M. D., Quindós, G., Pontón, J., & Arévalo, M. P. (2006) · Microbial Drug Resistance · doi:10.1089/mdr.2006.12.246 · Cited by 7
Mycology and Antifungal Susceptibility Testing
(2010) · doi:10.1128/9781555817435.ch8 · Cited by 6
Antifungal Drug Resistance: Clinical Relevance and Impact of Antifungal Drug Use
Drew, R. H., & Townsend, M. L. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0013-y · Cited by 5
Amsden, J. R. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-015-0223-4 · Cited by 5
Molecular Detection of Antifungal Resistance
Edlind, T. D. (2011) · Molecular Microbiology · doi:10.1128/9781555816834.ch44 · Cited by 5
Tosrisawatkasem, O., Thairat, S., Tonput, P., & Tantivitayakul, P. (2025) · BMC Oral Health · doi:10.1186/s12903-025-06334-2 · Cited by 4
Screening for drug-resistantCandidayeasts with chromogenic agar
Kirkpatrick, W. R., Zimmerman, J. D., Haikal, F. P., Broker, M. J., Brockway, E., Fothergill, A. W., McCarthy, D. I., Patterson, T. F., & Redding, S. W. (2010) · Medical Mycology · doi:10.3109/13693780903514542 · Cited by 4
Antifungal Pharmacokinetics and Pharmacodynamics
Andes, D. R., & Lepak, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_8 · Cited by 4
Self-citationPierantoni, D. C., Giuliano, S., Conti, A., Corte, L., Angelini, J., Cardinali, G., & Tascini, C. (2024) · Journal of Fungi · doi:10.3390/jof10070460 · Cited by 3
Sisniega, J. L., Profant, M., Kostřica, R., & Waskin, H. A. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.002 · Cited by 3
Pharmacokinetics and Pharmacodynamics of Azoles
Mouton, J. W. (2007) · CRC Press eBooks · doi:10.3109/9781420017137-20 · Cited by 3
Mushi, M. F., Loi, N., & Mshana, S. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211016964 · Cited by 3
Colonización por Candida en una unidad de cuidados intensivos neonatales
Caballero-Trejo, A., Aguirre-Morales, C. E., González-González, G. M., Cortés-Palma, D., & Miranda-Novales, M. G. (2014) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 3
Jones, R. N., Castanheira, M., & Pfaller, M. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00330-10 · Cited by 3
Self-citationEvaluation of VITEK-2 Antifungal Susceptibility Test (AST-YS01) forCandidaSpecies Isolates in Korea
Kim, D., Shin, J. H., Kee, S. J., Kim, S., Shin, M., Suh, S., & Ryang, D. W. (2009) · Korean Journal of Clinical Microbiology · doi:10.5145/kjcm.2009.12.3.122 · Cited by 3
Advances in Antifungal Susceptibility Testing of Candida, 2010–2012
Pfaller, M. A., Castanheira, M., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0092-z · Cited by 3
Self-citationPharmacokinetics and Pharmacodynamics of?Azoles
Mouton, J. W. (2007) · Infectious disease and therapy · doi:10.3109/9781420017137.017 · Cited by 3
Fleck, R., & Hof, H. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01568.x · Cited by 3
What is the role of therapeutic drug monitoring in antifungal therapy?
Smith, J. A. (2009) · Current Infectious Disease Reports · doi:10.1007/s11908-009-0064-9 · Cited by 3
Maheux, A. F., Sellam, A., Piché, Y., Boissinot, M., Pelletier, R., Boudreau, D. K., Picard, F. J., Trépanier, H., Boily, M.-J., Ouellette, M., et al. (2016) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2016.09.020 · Cited by 2
Pradhan, D. S., Agrawal, E., Murthy, R., & Tomar, D. R. (2017) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2017.i03.12 · Cited by 2
Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy
Lepak, A. J., & Andes, D. R. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0003-5 · Cited by 2
Self-citationArıkan, S., & Rex, J. H. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_36 · Cited by 2
Self-citationCermeño, J. R., Alvarado, P., Mendoza, M., Herndndez, I., & Cuestal, D. (2015) · PubMed · Cited by 2
Susceptibility Testing Agents of Subcutaneous Mycoses (Sporotrichosis and Chromoblastomycosis)
Treviño‐Rangel, R. D. J., & González, G. M. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-015-0232-3 · Cited by 2
Andes, D. R., & Dismukes, W. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_5 · Cited by 3
Self-citationBoy, S., Ardahanlı, H., Gören, K., Manap, S., & Yüksek, H. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146893 · Cited by 1
Öz, Y. (2014) · British Microbiology Research Journal · doi:10.9734/bmrj/2014/6950 · Cited by 1
Current Controversies in the Treatment of Fungal Infections
Pfeiffer, C. D., Perfect, J. R., & Alexander, B. D. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-644-3_27 · Cited by 1
Ranji, N., Sharami, S. H., Golpour, H., Koohpar, Z. K., Anvari, M., & Nikokar, I. (2020) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416820020081 · Cited by 1
Pharmacokinetics of voriconazole in horses and alpacas
Chan, H. M. (2008) · Cited by 1
Kundu, G. G. (2010) · Human Biology
Matos, T., Zver, S., Seme, K., Čižman, M., & Ravnik, J. (2008) · Slovenian Medical Journal · doi:10.6016/490
Estudio de los factores de patogenicidad de Cryptococcus gattii
Ramírez, A., & Eidi, V. (2008) · TDX (Tesis Doctorals en Xarxa)
Jones, R. J., Moet, G., Sader, H., Kirby, J., Messer, S., & Castanheira, M. (2009)
Pam, V. K., Akpan, J. U., Oduyebo, O. O., Nwaokorie, F. O., Fowora, M. A., Ogunsola, F. T., & Smith, S. I. (2012)
Saitoh, T., Matsushima, T., Shimizu, H., Osaki, Y., Yamane, A., Irisawa, H., Yokohama, A., Uchiumi, H., Handa, H., Tsukamoto, N., et al. (2008) · PubMed · doi:10.11406/rinketsu.49.94 · Cited by 5
Boutoille, D., Tattevin, P., Weinbreck, P., Ansart, S., Hutin, P., Leautez-Nainville, S., Raffi, F., Hôtel-Dieu, C., & de Limoges, C. (2009)
Pharmacokinetic–Pharmacodynamic Basis of Optimal Antibiotic Therapy
Neely, M. N., & Reed, M. D. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7020-3468-8.50297-2
Nett, J. E., & Andes, D. R. (2010) · CRC Press eBooks · doi:10.1201/b13787-154
Self-citationBendel, C. M., & Swanson, E. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00044-5
Influence of Fluconazole Resistance and Susceptibility on Candida –Streptococci Aggregation Dynamics
Karched, M., Hanif, A., Bhardwaj, R. G., Khalaf, M. E., & Qudeimat, M. A. (2025) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.70034
La D-cateslytine : un nouvel agent antifongique pour le traitement de la candidose buccale
Dartevelle, P. (2019) · theses.fr (ABES) · doi:10.70675/2fcc1c48z0776z40d4z8d81z66bc68fa13a9
Ismayilova, S. Z., Ismayilov, R. H., Peng, C., Song, Y., Huseynova, M., Tagiyev, D. B., Medjidov, A., Yalçın, B., Sertçelik, M., Ardahanlı, H., et al. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147100
Antifungal drug-loaded ionic liquid-in-water emulsion for nail fungal infections
Wang, J., Li, Y., Duncan, R., Chaturvedi, D., Faísca, F., Cao, Y., Thakur, R. R. S., Gilmore, B., Donnelly, R. F., & Vora, L. K. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127374
Moris, D. V. (2010) · Americanae (AECID Library)
Pires, R. H. (2010) · Americanae (AECID Library)
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Troke, P., Walsh, T. J., & Warnock, D. W.
- Affiliations
- University of Iowa (US)
- AstraZeneca (United Kingdom) (GB)
- VCU Medical Center, Richmond, Virginia
- HPA Centre for Infections, Kingsdown, Bristol, United Kingdom
- University of Wisconsin–Madison (US)
- New York State Department of Health (US)
- Case Western Reserve University (US)
- University of Aberdeen (GB)
- The University of Texas at San Antonio Health Science Center (US)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- National Institutes of Health (US)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Pfaller, M. A.
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2006-03
- Volume
- 44
- Issue
- 3
- Pages
- 819-826
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC1393146
- OpenAlex
- W2138433856
- Cited by
- 258
- References
- 43
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 12 · 2014: 8 · 2013: 5 · 2012: 16
- FWCI
- 25.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- voriconazole, Candida species, interpretive breakpoints, minimum inhibitory concentration, antifungal susceptibility, MIC distribution, antifungal resistance
- MeSH terms
- Antifungal Agents, Candida, Candidiasis, Data Interpretation, Statistical, Humans, Microbial Sensitivity Tests, Pyrimidines, Triazoles, Fluconazole, Inhibitory Concentration 50, Endpoint Determination, Drug Resistance, Fungal, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
